These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18295073)

  • 1. Biological action of rapamycin in renal transplantation.
    Weichhart T; Werzowa J; Hörl WH; Säemann MD
    Am J Kidney Dis; 2008 Mar; 51(3):531; author reply 531-2. PubMed ID: 18295073
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitoring biological action of rapamycin in renal transplantation.
    Leogrande D; Teutonico A; Ranieri E; Saldarelli M; Gesualdo L; Schena FP; Di Paolo S
    Am J Kidney Dis; 2007 Aug; 50(2):314-25. PubMed ID: 17660033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy.
    Hartmann B; Schmid G; Graeb C; Bruns CJ; Fischereder M; Jauch KW; Heeschen C; Guba M
    Kidney Int; 2005 Dec; 68(6):2593-8. PubMed ID: 16316335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of low-dose rapamycin on tumor growth in two human hepatocellular cancer cell lines.
    Heuer M; Benkö T; Cicinnati VR; Kaiser GM; Sotiropoulos GC; Baba HA; Treckmann JW; Broelsch CE; Paul A
    Transplant Proc; 2009; 41(1):359-65. PubMed ID: 19249557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecule of the month. Everolimus.
    Drug News Perspect; 2004 Mar; 17(2):142. PubMed ID: 15098068
    [No Abstract]   [Full Text] [Related]  

  • 6. p70S6 kinase phosphorylation for pharmacodynamic monitoring.
    Hartmann B
    Clin Chim Acta; 2012 Sep; 413(17-18):1387-90. PubMed ID: 22531277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leucine induces phosphorylation and activation of p70S6K in cortical neurons via the system L amino acid transporter.
    Ishizuka Y; Kakiya N; Nawa H; Takei N
    J Neurochem; 2008 Jul; 106(2):934-42. PubMed ID: 18435829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pro- and antitumor effects of the main immunosuppressive drugs used in the clinical practice of transplantation].
    Marchini F
    G Ital Nefrol; 2007; 24(2):171. PubMed ID: 17458835
    [No Abstract]   [Full Text] [Related]  

  • 9. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma.
    Baba HA; Wohlschlaeger J; Cicinnati VR; Hilgard P; Lang H; Sotiropoulos GC; Takeda A; Beckebaum S; Schmitz KJ
    Liver Int; 2009 Mar; 29(3):399-405. PubMed ID: 18492014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Everolimus].
    Michels G; Hoppe UC
    Dtsch Med Wochenschr; 2005 Oct; 130(40):2263-5. PubMed ID: 16208601
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy.
    Harding MW
    Clin Cancer Res; 2003 Aug; 9(8):2882-6. PubMed ID: 12912931
    [No Abstract]   [Full Text] [Related]  

  • 12. P70 S6 kinase assay: a pharmacodynamic monitoring strategy for rapamycin; assay development.
    Gallant HL; Yatscoff RW
    Transplant Proc; 1996 Dec; 28(6):3058-61. PubMed ID: 8962186
    [No Abstract]   [Full Text] [Related]  

  • 13. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors.
    Cruzado JM
    Transplant Rev (Orlando); 2008 Jan; 22(1):73-81. PubMed ID: 18631860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.
    Böhler T; Waiser J; Lichter S; Schumann B; Neumayer HH; Kamar N; Budde K
    Cytokine; 2008 Jun; 42(3):306-11. PubMed ID: 18440821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression.
    Sehgal SN
    Clin Biochem; 1998 Jul; 31(5):335-40. PubMed ID: 9721431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation.
    Campistol JM; Cockwell P; Diekmann F; Donati D; Guirado L; Herlenius G; Mousa D; Pratschke J; San Millán JC
    Transpl Int; 2009 Jul; 22(7):681-7. PubMed ID: 19386082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin plays a new role as differentiator of vascular smooth muscle phenotype. focus on "The mTOR/p70 S6K1 pathway regulates vascular smooth muscle differentiation".
    Lucchesi PA
    Am J Physiol Cell Physiol; 2004 Mar; 286(3):C480-1. PubMed ID: 14761882
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibitors of the mammalian target of rapamycin and transplant tolerance.
    Bestard O; Cruzado JM; Grinyó JM
    Transplantation; 2009 Apr; 87(8 Suppl):S27-9. PubMed ID: 19384184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [3/3 Inhibitors of mTOR (sirolimus and everolimus)].
    Chaumard N; Limat S; Woronoff-Lemsi MC
    Soins; 2007 Sep; (718):63-4. PubMed ID: 17970580
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.